Bluebird Bio To Present At Three Upcoming Health Care Conferences
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present
at the Deutsche Bank 39
th Annual Health Care Conference on
Thursday, May 8, 2014 at 8:00 AM( EDT) at the InterContinental Boston
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Deutsche Bank 39 th Annual Health Care Conference on Thursday, May 8, 2014 at 8:00 AM( EDT) at the InterContinental Boston Hotel, Boston, Massachusetts. Management will also present at the Bank of America Healthcare Conference on Wednesday, May 14, 2014 at 3:40 PM (PDT) at the Encore at Wynn Hotel, Las Vegas, Nevada and at the UBS Global Healthcare Conference on Wednesday, May 21, 2014 at 11:00 AM (ET) at the Sheraton New York Hotel, New York, New York. To access a simultaneous webcast of these presentations via the internet, log on to the "Calendar of Events" section on the Investor and Media page of the bluebird bio website at http://investor.bluebirdbio.com. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast. A replay of the webcasts will be available on bluebird bio website for ninety days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Calendar of Events" section of the Investor and Media page of the bluebird bio's website at http://investor.bluebirdbio.com. About bluebird bio, Inc. bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases. bluebird bio has two clinical-stage programs in development. The most advanced product candidate, Lenti-D, is in a recently-initiated phase 2/3 study, the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder affecting young boys. The next most advanced product candidate, LentiGlobin, is currently in two phase 1/2 studies, one in the US (the Northstar Study) and one in France (HGB-205), for the treatment of beta-thalassemia major. The phase 1/2 HGB-205 study also allows enrollment of patient(s) with sickle cell disease, and bluebird bio is planning a separate U.S. sickle cell disease trial in which the first patient is expected to enroll in 2014.